Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Byotrol Plc LSE:BYOT London Ordinary Share GB00B0999995 ORDS 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.20 3.45% 6.00 5.90 6.10 6.00 5.80 5.80 1,113,224 15:07:17
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Chemicals 6.1 -0.0 0.1 75.0 27

Byotrol Share Discussion Threads

Showing 9451 to 9473 of 10675 messages
Chat Pages: Latest  379  378  377  376  375  374  373  372  371  370  369  368  Older
DateSubjectAuthorDiscuss
15/5/2020
11:49
1gw, You claim to have attended the agm and spoken about US contracts and are now suggesting that Byot will make millions from Royalties this year. Looking at your list, you're suggesting they will make £17m revenues from products and royalties. Byot have only stated orders for Q1. Finncap have currently stated £9m, so neither are suggesting anything near your figures. Advanced Hygienics (AH) has been a partner for THREE yrs. Have they had meaningful royalties over the last 3 yrs? Royalties from an established deal would give a rough idea as to what can be expected. Was it £millions then? 1gw14 May '20 - 17:37 - 5918 of 5960 2.000 6 1 Just as a reminder of the building blocks for this year: £12m product sales (annual based on Mar-May run rate) £ m royalty/minimum guaranteed payment Americas byotrol24 £ m royalty/minimum guaranteed payment SC Johnson Invirtu £ m royalty/minimum guaranteed payment Tristel/Cache £ m royalty/minimum guaranteed payment Solvay Actizone £ m royalty Tristel new formulation (+ any increase in actizone supply sales over Apr-May rate) Now some of the £m may be £k this year, but it seems to me byotrol is putting together an impressive portfolio of licence deals. And even so you could argue it is only just getting started: how many more deals can it do like the Tristel/Cache one to license non-core technologies to companies whose products are under regulatory threat? how many more geographies could it license byotrol24 in? can it license Invirtu in various geographies, or will meaningful royalties come in from the US red cross deal if Advanced Hygienics can find funding for marketing and production?
sikhthetech
15/5/2020
11:28
1gw, You still ignoring the question... Advanced Hygienics has been a partner for 3 yrs. Have they had meaningful royalties over the last 3 yrs? Or is it all baseless ramping as usual... I see lots of tiny trades going through £5.60, £47.49, £57.98 etc etc... Is that you and your mates 1gw to push up the share price to make it look like there's interest... explains the long baseless ramping posts, doesn't it?
sikhthetech
15/5/2020
10:59
Too early to comment on 'good cashflow'. They missed the cash expectation for March 2020 and have had declining cash balances for years. Most of what you say is baseless ramping. Best read the company news...
sikhthetech
15/5/2020
10:54
That's part of normal working capital calculations and since they refer to an invoice discounting facility in the April TU, clearly they have a way of monetising receivables to finance growth if they need to. But cashflow should look good this year I would have thought. They've lost the costs of the US business, lost the supply costs for SC Johnson and don't have any contingent payment to make to Medimark sellers. They also expect to deliver some synergies from the Medimark integration. They have the up-front from the byotrol24 deal and any royalty payments (quarterly for byotrol24) or minimum guaranteed payments that are due. They already received £0.3m [edit: £ not $] on 2nd April, which I guess is the minimum guaranteed payment on the Solvay deal that was due last year. So plenty of cash positives to offset increased working capital associated with growth of the product supply business. They could presumably monetise some of the future stream of minimum guaranteed payments on the various licensing deals as well if they needed to.
1gw
15/5/2020
10:27
1gw "building their own manufacturing plant? i.e. they effectively rent capacity in someone else's manufacturing plant." Yes and where in my post did I say that they need to build a manufacturing plant to increase capacity? I said: "With £1.7m cash, as of 31st March, I wonder if they will have a placing soon to help pay for increasing capacity?" Let me rephrase it in a simpler way for you then... Given they are selling all they can make, how much extra rent would they have to pay to increase capacity.. Say they wish to double the current output.
sikhthetech
15/5/2020
10:16
You understand that byotrol operate a tolling model rather than building their own manufacturing plant? i.e. they effectively rent capacity in someone else's manufacturing plant. And of course where they outlicense the technology, such as Americas byotrol24, SC Johnson, Tristel Cache and Solvay, it is the licensee that is responsible for manufacture.
1gw
15/5/2020
10:02
If they had to increase manufacturing capacity then have they got the cash to do so? With £1.7m cash, as of 31st March, I wonder if they will have a placing soon to help pay for increasing capacity? Cash balances have been declining for years.. Cash: fy2018 £3.85m fy2019 £2.8m H12020 £2.01m fy2020 £1.7m (expectation was £2.6m)
sikhthetech
15/5/2020
08:03
Riddlerone, "Manufacturing capability".. Given they are already 'selling all they make" how much would it cost to increase manufacturing capability?
sikhthetech
15/5/2020
08:01
Given it is "only" a 10 year deal with "material minimum annual guaranteed payments" the licensees are incentivised to get on with it I would have thought. And that's in addition to common sense dictating that they should try to catch the current demand spike. I would hope they have a supply chain ready to go and have a contract pretty much ready with 1 or more retailers. I'm watching the byotrol24 site and the facebook page to see when the message on (un)availability there changes.
1gw
15/5/2020
07:45
If ever there was a time for Byotrol 24 to be relaunched its now.I wonder how quickly they will have a supply chain and manufacturing capability in place?
riddlerone
15/5/2020
07:21
One interesting thing about the US deal is that it is a time-limited licence agreement, rather than a farm-in type deal. Originally I think they were hoping to get someone to farm in, ie to earn equity in the product by funding the $5m marketing spend they believed was necessary to achieve sales materiality, although at the AGM they said they were open to any form of commercial deal. A farm-in would have left byotrol with equity, which would have likely produced higher profits in a success case, but would have left it having to fund some of the development spend - as well as the marketing spend there would be costs to scale up the supply chain and working capital tied up as they expanded and while they might have got an investment partner to fund some of the supply chain spend (disproportionately) it was perhaps unrealistic to expect a complete carry. So a licence agreement leaves them with no material costs in the US, and therefore essentially just a contribution to profit and cashflow from royalty income. What we don't know yet is the scale of the royalty - in biotech deals it is usual to indicate a range such as "low single digits" and it would be helpful if the company could indicate something like this (or even some form of aggregate figure for a number of licence deals) in a future update. At least the royalty is quarterly so once byotrol24 is back on the shelves we should see the royalty show up in the results. I notice the licence is not just for the US, but for "the Americas". This expanded geographic scope was perhaps traded off against the 10 year limit. The limit is interesting in that in a success case, where byotrol24 establishes itself as a profitable player in one or more Americas markets, byotrol will have something valuable at the end of the licence term - a chunky "residual value" for analysts to feed into their valuation models.
1gw
15/5/2020
07:16
Maybe we need a new thread with a new start and a view to get rid of infestations like Ticks
riddlerone
15/5/2020
07:14
If everyone filtered sickbag he'd never get any reaction to any of his posts and would go away. Byotrol's shares went from under 2p to over 7p despite all those posts. No-one is taking any notice of him so just filter the weirdo and this board will calm down a lot. I live in blissful ignorance of whatever nonsense is being spouted.
tradertrev
15/5/2020
07:14
1gw, You mentioned meaningful Royalties from AH but still have avoided my question.. Advanced Hygienics has been a partner for 3 yrs. Have they had meaningful royalties over the last 3 yrs? Also Whatever happened to Rentokil? Was that also a multi year deal?
sikhthetech
15/5/2020
07:09
1gw, Given your huge confidence in the company's future, I assume you won't be selling any, Will you? Or are you and your mates pumping and dumping like you have done before. Trades are traceable.
sikhthetech
15/5/2020
06:59
23 posts here yesterday from you, sikhthetech, and starting early again today I see. Using coins to promote your own posts apparently (a bit of a giveaway when a promoted post has zero thumbs up) and to hide posts that others have promoted. How does all that fit with allowing other posters to make up their own mind?
1gw
15/5/2020
06:42
They have a £1m a month run rate when there is a surge in demand. They also stated the supply chain is working well. They also expect demand to fall back at some point and have stated sales for Q1 only, end of next month. I think that spike in sales is already factored in the share price Finncap currently saying around £9m revenues for the year. That compares to £6m revenue for last year, to March 31st 2020. Read the company and broker report and form your own opinion.
sikhthetech
15/5/2020
05:30
Good coverage for BYOT in this morning's Mail, where it's the featured stock in their market report: Https://www.thisismoney.co.uk/money/markets/article-8321073/MARKET-REPORT-Stark-warnings-virus-sends-shares-plunging.html "Stock Watch - Byotrol Disinfectant maker Byotrol surged 16.8 per cent, or 0.79p, to 5.5p after it signed licensing deals and said first-quarter sales would hit a record high. Demand for the group's products has surged amid the coronavirus pandemic, with sales of more than £1million in both March and April. The AIM-listed group has struck a 10-year licensing agreement in the US for its long-lasting sanitiser spray and a contract with SC Johnson, also in America, for its alcohol-free hand sanitisers."
rivaldo
14/5/2020
23:14
Ah, coins now being removed to keep 1GW's last post out of the header. Says it all really. So how's that short STT?
milesy
14/5/2020
22:50
STT is year 6 so fingers crossed he goes back on the 1st of June. I'm at big school so probably not until the start of September
techair
14/5/2020
22:49
This is a company producing products to help protect against the virus. You continue to spout your vitriol against Byotrol. Why don’t you do something useful like volunteer to help the NHS seeing as you are so concerned
mutley28
14/5/2020
22:31
"1gw tries to portray a persona of a knowledgeable person, writing long well written posts" Like I said, pot, kettle, black....the bold red text just highlights the desparation. So how's the short?
milesy
14/5/2020
22:23
FFS. I really hope the schools are re-opened soon.
eeza
Chat Pages: Latest  379  378  377  376  375  374  373  372  371  370  369  368  Older
ADVFN Advertorial
Your Recent History
LSE
BYOT
Byotrol
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201128 11:26:30